UnitedHealth Group shares rose Wednesday after the company's insurance unit announced a significant reduction in prior authorization requirements, aiming to streamline care while maintaining cost controls. UNH traded at $367.55, up roughly 1% for the session, with an intraday range of $358.24 to $368.50.
Key Changes to Prior Authorization
UnitedHealthcare plans to eliminate prior authorization for 30% of medical services that still require it by the end of 2026. The affected services include select outpatient surgeries, diagnostic tests such as echocardiograms, outpatient therapies, and chiropractic care. The company noted that prior authorization now applies to only 2% of its medical services, and approximately 92% of those requests are approved within 24 hours on average.
Industry Context
The move comes amid broader industry efforts to reduce administrative burdens. In April, UnitedHealth and CVS Health aligned data and submission requirements for over half of their prior authorizations. CVS's Aetna reported that 88% of its authorizations were standardized at that point. UnitedHealthcare emphasized that the updates will not alter coverage criteria or medical standards for approving or denying care.
Financial Performance
UnitedHealth Group reported first-quarter revenue of $111.7 billion, with adjusted earnings of $7.23 per share. The company raised its full-year adjusted profit outlook to above $18.25 per share. Its medical cost ratio improved to 83.9%, down from 84.8% in the same period last year. Analysts viewed the results as a positive sign for the health insurance sector after a challenging period. Mizuho's Ann Hynes called it a "positive quarter," noting that medical cost acceleration appeared to have peaked. Oppenheimer's Michael Wiederhorn suggested UnitedHealth could return to its "beat-and-raise" pattern.
Rival Performance
CVS Health shares surged over 9% after the company raised its 2026 profit forecast, citing tighter cost controls at Aetna and stronger pharmacy-benefit performance. Aetna's medical loss ratio came in at 84.6%, beating analyst expectations. However, both UnitedHealth and Humana have flagged ongoing pressure from Medicare Advantage costs.
Risks and Outlook
While reducing prior authorization may ease frustrations among doctors and patients, it could lead to higher utilization and scrutiny over cost management. UnitedHealth's first-quarter materials indicated that utilization and unit-cost trends remained elevated despite improved medical cost controls. Investors are now focused on the second-quarter medical cost ratio, the final list of services exempt from prior authorization, and whether Medicare Advantage trends will continue to improve.
